Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RPTX |
---|---|---|
09:32 ET | 1878 | 3.75 |
09:34 ET | 500 | 3.7148 |
09:36 ET | 699 | 3.78 |
09:38 ET | 5840 | 3.75 |
09:39 ET | 400 | 3.75 |
09:41 ET | 200 | 3.76 |
09:43 ET | 790 | 3.78 |
09:45 ET | 1100 | 3.76 |
09:48 ET | 200 | 3.78 |
09:50 ET | 200 | 3.78 |
09:52 ET | 160 | 3.78 |
09:54 ET | 1422 | 3.7947 |
09:56 ET | 997 | 3.7598 |
09:57 ET | 200 | 3.8 |
09:59 ET | 1239 | 3.74 |
10:06 ET | 100 | 3.755 |
10:08 ET | 206 | 3.75 |
10:10 ET | 759 | 3.75 |
10:12 ET | 2000 | 3.74 |
10:14 ET | 1775 | 3.72 |
10:15 ET | 100 | 3.72 |
10:17 ET | 18552 | 3.68 |
10:19 ET | 300 | 3.68 |
10:21 ET | 600 | 3.7 |
10:26 ET | 200 | 3.68 |
10:28 ET | 100 | 3.67 |
10:30 ET | 1900 | 3.65 |
10:32 ET | 200 | 3.6413 |
10:46 ET | 100 | 3.64 |
10:48 ET | 200 | 3.67 |
10:50 ET | 100 | 3.66 |
10:51 ET | 1000 | 3.6699 |
10:53 ET | 100 | 3.66 |
11:02 ET | 1944 | 3.64 |
11:06 ET | 700 | 3.6 |
11:08 ET | 300 | 3.61 |
11:11 ET | 1301 | 3.6 |
11:15 ET | 2361 | 3.5911 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Repare Therapeutics Inc | 156.6M | -3.3x | --- |
AVITA Medical Inc | 225.0M | -4.8x | --- |
Genfit SA | 183.9M | -6.0x | --- |
Precision BioSciences Inc | 80.4M | -2.2x | --- |
Champions Oncology Inc | 63.1M | -6.3x | --- |
Innate Pharma SA | 202.8M | -25.0x | --- |
Repare Therapeutics Inc. is a clinical-stage precision oncology company focused on the development of synthetic lethality (SL)-based therapies for patients with cancer. The Company is engaged in the proprietary SL approach to the discovery and development of novel therapeutics. It uses its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The Company’s initial product candidate, camonsertib (RP-3500 or RG6526), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated kinase (ATM) gene as part of a network of 16 STEP2-identified genomic alterations. Its other pipeline includes Lunresertib PKMYT1 Inhibitor and RP-3467 polymerase theta (Pol0) Inhibitor.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $156.6M |
---|---|
Revenue (TTM) | $97.9M |
Shares Outstanding | 42.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.74 |
EPS | $-1.10 |
Book Value | $5.03 |
P/E Ratio | -3.3x |
Price/Sales (TTM) | 1.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -72.27% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.